Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

Trial Profile

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms IMpassion030
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 02 Aug 2018 Planned initiation date (estimated date for accrual of the first patient) changed from 25 Apr 2018 to 1 Aug 2018.
    • 17 May 2018 Status changed from not yet recruiting to recruiting.
    • 20 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top